2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173395
    MAO-B-IN-43 98%
    MAO-B-IN-43 (4) is a potent hMAO-B inhibitor and a weak GSK3β kinase inhibitor, with Ki values of 0.044 μM and 0.004 μM for hMAO-A and hMAO-B, respectively. MAO-B-IN-43 (4) can be used for the research of neurodegenerative disorder.
    MAO-B-IN-43
  • HY-173398
    NMDAR antagonist 5 3038464-68-2 98%
    NMDAR antagonist 5 (Compound A17) is a multi-target antagonist against NMDAR and monoamine transporters (SERT、DAT and NET). NMDAR antagonist 5 shows good NMDAR antagonistic potency (IC50 = 0.3 μM) and monoamine transporter activities (SERT IC50 = 1.1 μM、DAT IC50 = 0.7 μM、NET IC50 = 2.7 μM). NMDAR antagonist 5 is highly safe and has low toxicity (hepatotoxicity and nephrotoxicity (IC50 > 100 μM); cardiotoxicity (IC50 = 24.5 μM)). NMDAR antagonist 5 has antidepressant effects and can be used in the study of depression.
    NMDAR antagonist 5
  • HY-173430
    AD015 177741-43-4 98%
    AD015 is a angiotensin-converting enzyme (ACE) and neprilysin (NEP) dual inhibitor. AD015 inhibits NEP, nACE and cACE with IC50s of 0.009, 0.019 and 0.0008 μM, respectively.
    AD015
  • HY-173449
    TRPM2-IN-1 2833727-43-6 98%
    TRPM2-IN-1 (compound D10) is a potent TRPM2 inhibitor. TRPM2-IN-1 exhibits antistroke activity and significant neuroprotective effect. TRPM2-IN-1 can be used in the study of ischemic stroke.
    TRPM2-IN-1
  • HY-173451
    TAAR1/5-H-2CR agonist-1 3024777-79-2 98%
    TAAR1/5-H-2CR agonist-1 (compound 21b) is a TAAR1 and 5-HT2CR dual agonist with EC50s of 0.022 and 0.246 μM, respectively. TAAR1/5-H-2CR agonist-1 can used in the study of schizophrenia and Alzheimer's Disease.
    TAAR1/5-H-2CR agonist-1
  • HY-173471
    TRPA1 agonist-1 98%
    TRPA1 agonist-1 (compound 21) is a potent and selective TAAR1 agonist with an EC50 of 25.47 μM. TRPA1 agonist-1 shows effective analgesic properties without irritation in mice.
    TRPA1 agonist-1
  • HY-173475
    CM699 1259949-84-2 98%
    CM699 is a potent Dopamine Transporter (DAT) and Sigma-receptor (σR) dual inhibitor with IC50s of 311 and 14.1 nM, respectively.
    CM699
  • HY-173486
    BuChE-IN-21 98%
    BuChE-IN-21 (compound SXF3) is a potent and selective BuChE inhibitor. BuChE-IN-21 inhibits eqBuChE and hBuChE with IC50s of 0.05 and 0.04 μM, respectively. BuChE-IN-21 has high anti-inflammatory activity.
    BuChE-IN-21
  • HY-173509
    ATX inhibitor 27 2023027-81-6 98%
    ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC50 values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer.
    ATX inhibitor 27
  • HY-173513
    IDO1/TDO-IN-8 3085413-22-2 98%
    IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression.
    IDO1/TDO-IN-8
  • HY-173516
    CCR5-IN-1 98%
    CCR5-IN-1 (compound 3ad) is a selective allosteric CCR5 inhibitor with an IC50 of 1.09 μM. CCR5-IN-1 can be used in the study of cardiovascular, central nervous system, immune system, and infectious diseases.
    CCR5-IN-1
  • HY-173540
    C22:1 1-Deoxyceramide (m18:1/22:1)
    C22:1 1-Deoxyceramide (m18:1/22:1) (C22:1(13Z) 1-Deoxyceramide) is a deoxyceramide lipid that lacks the 1-hydroxyl group and is a ceramide variant. C22:1 1-Deoxyceramide (m18:1/22:1) has potential neurotoxicity and is involved in mitochondrial stress and cell death signaling. It can be used to study abnormal sphingolipid metabolism and neurodegenerative diseases.
    C22:1 1-Deoxyceramide (m18:1/22:1)
  • HY-173543
    MDA-19 N-(5-hydroxyhexyl)
    MDA-19 N-(5-hydroxyhexyl) is a cannabinoid receptor modulator targeting CB1R/CB2R. MDA-19 N-(5-hydroxyhexyl) is used to study neurological diseases, cancer, and pain regulation.
    MDA-19 N-(5-hydroxyhexyl)
  • HY-17355S
    Pramipexole-d7 dihydrochloride 98%
    Pramipexole-d7 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole-d7 dihydrochloride
  • HY-173574
    RIPK1-IN-31 2857845-45-3
    RIPK1-IN-31 (Compound 36) is a selective allosteric modulator of RIPK1 (receptor-interacting protein kinase 1) with an IC50 value of 16 nM. RIPK1-IN-31 is promising for research of infectious, autoimmune, and neurodegenerative diseases.
    RIPK1-IN-31
  • HY-17360R
    Tiotropium Bromide (Standard) 136310-93-5 98%
    Tiotropium (Bromide) (Standard) is the analytical standard of Tiotropium (Bromide). This product is intended for research and analytical applications. Tiotropium bromide (BA-679 BR) is a long-acting anticholinergic bronchodilator. Tiotropium bromide blocks the action of acetylcholine at muscarinic M1, M2, and M3 receptors, prevents bronchoconstriction, and dilates bronchial airways. Tiotropium bromide is applicable to research related to chronic obstructive pulmonary disease and asthma.
    Tiotropium Bromide (Standard)
  • HY-17360S
    Tiotropium-d3 bromide 1127226-56-5 98%
    Tiotropium-d3 (bromide) is the deuterium labeled Tiotropium (Bromide). Tiotropium bromide (BA-679 BR) is a long-acting anticholinergic bronchodilator. Tiotropium bromide blocks the action of acetylcholine at muscarinic M1, M2, and M3 receptors, prevents bronchoconstriction, and dilates bronchial airways. Tiotropium bromide is applicable to research related to chronic obstructive pulmonary disease and asthma.
    Tiotropium-d3 bromide
  • HY-173615
    KTD-092 98%
    KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases.
    KTD-092
  • HY-173616
    GABAA receptor modulator-8 2889382-34-5 98%
    GABAA receptor modulator-8 (10c) is a blood-brain barrier penetrated, selective and positive modulator of GABAA receptor, with excellent antiepileptic activity.
    GABAA receptor modulator-8
  • HY-173621
    Aβ1–42 aggregation inhibitor 3 32527-84-7 98%
    Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC50 values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research.
    Aβ1–42 aggregation inhibitor 3
Cat. No. Product Name / Synonyms Application Reactivity